ACE and urticaria: Interestingly, Cugno M et al. (2021) noted that after COVID vaccination, the physiopathological basis of the higher risk of urticaria/angioedema in subjects taking ACE inhibitors may be the increase in bradykinin, a vasoactive peptide that induces vascular permeability and that is catabolized by ACE [238].